NCT07671911Phase 3Recruiting

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

Study sponsor: Trevi Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-06Estimated
Enrollment · participants306Estimated
Source updated2026-11-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source